Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Yangxueqingnao
- Development stage
- Phase 2
- Lead developer
- Beijing Hospital
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Yangxueqingnao is a Traditional Chinese Medicine (TCM) formulation developed by the Department of Neurology at Beijing Hospital and manufactured by Tasly Pharmaceutical Group. It is composed of 11 herbal extracts, including *Angelica sinensis*, *Ligusticum chuanxiong*, and *Uncaria rhynchophylla*. Primarily indicated for the treatment of chronic cerebral circulation insufficiency, tension-type headaches, and vascular cognitive impairment non-dementia (VCIND), the drug exerts its effects by improving cerebral blood flow, reducing blood viscosity, and providing neuroprotective benefits through antioxidant and anti-inflammatory pathways. It is widely used in China to alleviate symptoms such as dizziness, headache, and insomnia associated with cerebrovascular disorders.
- Brand names
- Yangxue Qingnao GranulesYangxue Qingnao Wan
- Other names
- YXQNYangxue Qingnao
02
Targets
MAPT (Microtubule-associated protein tau)Aβ (Amyloid-beta peptides and aggregates)BACE1 (Beta-site APP-cleaving enzyme 1)
Beyond the preview
Go deeper on Yangxueqingnao.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Yangxueqingnao.